Sun Of India To Halt Colon-Cancer Generic In U.S. By July 31
This article was originally published in PharmAsia News
Executive Summary
India's Sun Pharma has been ordered by a U.S. federal court to cease marketing its generic version of the Sanofi-Aventis drug Eloxatin (oxaliplatin) for treating colon cancer